ACB
Aurora Cannabis Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.95
+1.54%Year over year
Reported trailing growth
- Revenue
- -16.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +7.1%
- EBITDA
- +117.6%
- EPS
- +93.0%
Three-year CAGR
- Revenue
- +12.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026